E
Elmar Stickeler
Researcher at RWTH Aachen University
Publications - 130
Citations - 3086
Elmar Stickeler is an academic researcher from RWTH Aachen University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 25, co-authored 130 publications receiving 2108 citations. Previous affiliations of Elmar Stickeler include University of Freiburg & University Medical Center Freiburg.
Papers
More filters
Journal ArticleDOI
Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer-host interface.
Peter Bronsert,Kathrin Enderle-Ammour,Moritz Bader,Sylvia Timme,M Kuehs,Agnes Csanadi,Gian Kayser,Ilona Kohler,D Bausch,Jens Hoeppner,Ulrich T. Hopt,Tobias Keck,Elmar Stickeler,Bernward Passlick,Oliver Schilling,CP Reiss,Y Vashist,Thomas Brabletz,J. P. Berger,Johannes Lotz,Janine Olesch,Martin Werner,Ulrich F. Wellner +22 more
TL;DR: The relationship between current biological and clinical concepts such as cell migration modes, tumour budding and epithelial-mesenchymal transition (EMT) remains unclear in several aspects, especially for the'real' situation in human cancer as mentioned in this paper.
Journal ArticleDOI
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Carsten Denkert,Fenja Seither,Andreas Schneeweiss,Theresa Link,Jens-Uwe Blohmer,Marianne Just,Pauline Wimberger,A Forberger,Hans Tesch,Christian Jackisch,Sabine Schmatloch,Mattea Reinisch,Erich Solomayer,Wolfgang D. Schmitt,Claus Hanusch,Peter A. Fasching,Kristina Lübbe,Christine Solbach,Jens Huober,Kerstin Rhiem,Frederik Marmé,Toralf Reimer,Marcus Schmidt,Bruno Valentin Sinn,Wolfgang Janni,Elmar Stickeler,Laura Michel,Oliver Stötzer,Eric Hahnen,Jenny Furlanetto,Sabine Seiler,Valentina Nekljudova,Michael Untch,Sibylle Loibl +33 more
TL;DR: In this article, the authors compared the clinical and molecular characteristics of HER2-low-positive and HER2zero breast cancer, including response to neoadjuvant chemotherapy and prognosis.
Journal ArticleDOI
Motion model ultrasound localization microscopy for preclinical and clinical multiparametric tumor characterization.
Tatjana Opacic,Stefanie Dencks,Benjamin Theek,Marion Piepenbrock,Dimitri Ackermann,Anne Rix,Twan Lammers,Elmar Stickeler,Stefan Delorme,Georg Schmitz,Fabian Kiessling +10 more
TL;DR: Motion model ultrasound localization microscopy (mULM) is introduced as an easily applicable and robust new tool to morphologically and functionally characterize fine vascular networks in tumors at super-resolution and can be applied in a clinical ultrasound setting opening avenues for the multiparametric characterization of tumors and the assessment of therapy response.
Journal ArticleDOI
Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker
Thalia Erbes,Marc Hirschfeld,Marc Hirschfeld,Gerta Rücker,Markus Jaeger,Jasmin Boas,Severine Iborra,Sebastian Mayer,Gerald Gitsch,Elmar Stickeler +9 more
TL;DR: The feasibility to detect distinct BC-dependent urinary miRNA profiles is demonstrated for the first time and sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection.
Journal ArticleDOI
Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer
Eduardo Pérez-Gómez,Clara Andradas,Sandra Blasco-Benito,María M. Caffarel,Elena García-Taboada,María Villa-Morales,Estefanía Moreno,Sigrid Hamann,Ester Martín-Villar,Juana M. Flores,Antonia Wenners,Ibrahim Alkatout,Wolfram Klapper,Christoph Röcken,Peter Bronsert,Elmar Stickeler,Annette Staebler,Maret Bauer,Norbert Arnold,Joaquim Soriano,Manuel Pérez-Martínez,Diego Megías,Gema Moreno-Bueno,Silvia Ortega-Gutiérrez,Marta Artola,Henar Vázquez-Villa,Miguel Quintanilla,José Fernández-Piqueras,Enric I. Canela,Peter J. McCormick,Manuel Guzmán,Cristina Sánchez +31 more
TL;DR: The findings reveal an unprecedented role of CB2 as a pivotal regulator of HER2 pro-oncogenic signaling in breast cancer, and they suggest that CB2 may be a biomarker with prognostic value in these tumors.